Drug intelligence / Profile preview

nifedipine + LipoCol

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules

Overview

This is a combination product containing nifedipine and LipoCol. Nifedipine is a dihydropyridine calcium channel blocker that inhibits voltage-gated L-type calcium channels in vascular smooth muscle and myocardial cells, leading to vasodilation, reduced peripheral resistance, decreased blood pressure, and increased oxygen supply to the heart. It is primarily used for the treatment of hypertension and angina[1][2][3]. LipoCol refers to a brand name for red yeast rice extract (Monascus purpureus), which contains naturally occurring

Other names: nifedipine and red yeast rice extract

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on nifedipine + LipoCol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nifedipine + LipoCol.

Explore the full profile